A Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving Surgery

Background: Breast cancer became the most prevalent cancer globally in 2020, and post-surgery radiotherapy is crucial for most patients. Traditional radiotherapy is complex and time-consuming, affecting patient experience. To streamline this, an AI-assisted All-in-one (AIO) radiotherapy approach has been developed, integrating steps like target delineation and planning to reduce wait times and enhance accuracy. Preliminary results are promising, with significant time savings and high pass rates in initial assessments. Further exploration is needed to confirm the accuracy, effectiveness, and sa

Trial Details

NCT ID
NCT06686459
Phase
NA
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • ALL-in-one radiotherapy
  • IMRT
Locations (sample)
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • 1\. Female patients aged 18-70 years. 2. ECOG performance status of 0-2. 3. Newly diagnosed invasive breast cancer, underwent breast-conserving sur…
  • 4\. No distant metastasis. 5. Capable of tolerating radiotherapy. 6. For ER/PR-positive patients, willing to receive anticipated 5 years of endocri…
  • 7\. For HER2-positive patients, willing to receive anticipated 1 year of anti-HER2 targeted therapy.
  • 8\. For patients requiring neoadjuvant/adjuvant chemotherapy, must have completed chemotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →